



(12) Translation of
European patent specification

(11) NO/EP 3541807 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 295/205 (2006.01)
A61P 25/00 (2006.01)
A61P 29/00 (2006.01)
C07C 57/15 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2022.01.24
(80)	Date of The European Patent Office Publication of the Granted Patent	2021.09.29
(86)	European Application Nr.	17872429.0
(86)	European Filing Date	2017.11.15
(87)	The European Application's Publication Date	2019.09.25
(30)	Priority	2016.11.16, US, 201662423126 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
	Designated Validation States:	MA ; MD
(73)	Proprietor	H. Lundbeck A/S, Ottiliavej 9, 2500 Valby, Danmark
(72)	Inventor	GRICE, Cheryl A., 924 Springwood Lane, Encinitas, California 92024, USA JONES, Todd K., 546 Marview Drive, Solana Beach, California 92075, USA GRIMM, Kurt G., 2658 Del Mar Heights Road 249, Del Mar, California 92014, USA BLANKMAN, Jacqueline Lorayne, 11215 Lianres Street, San Diego, California 92129, USA BEALS, Channing Rodney, 4100 Twilight Ridge, San Diego, California 92130, USA
(74)	Agent or Attorney	BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge

(54)	Title	A CRYSTALLINE FORM OF A MAGL INHIBITOR
------	-------	---

(56)	References Cited:	WO-A1-2016/183097 WO-A2-2015/179559 US-A1- 2015 018 335
------	----------------------	---

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

PATENTKRAV

1. Krystallinsk form av 1,1,1,3,3,3-heksafluorpropan-2-yl-4-(2-(pyrrolidin-1-yl)-4-(trifluormetyl)benzyl)piperazin-1-karboksylat, hvor
5 den krystallinske form av 1,1,1,3,3,3-heksafluorpropan-2-yl 4-(2-(pyrrolidin-1-yl)-4-(trifluormetyl)benzyl)piperazin-1-karboksylat er mono-hydrokloridsaltet Form 2 som har et røntgenpulverdiffraksjonsmønster (XRPD) med karakteristiske topper ved 8,6° 2-Theta, 14,3° 2-Theta, 15,6° 2-Theta, 19,0° 2-Theta, 19,8°
10 2-Theta og 20,7 ° 2-Theta.
2. Farmasøytisk sammensetning omfattende den krystallinske formen ifølge krav 1, og minst én inaktiv ingrediens valgt fra farmasøytisk akseptable bærere, fortynningsmidler og eksipienser.
- 15 3. Krystallinsk form ifølge krav 1, for anvendelse i behandlingen av multippel sklerose.
4. Krystallinsk form ifølge krav 1, for anvendelse i behandlingen av
20 multippel sklerose ifølge krav 3, hvor behandlingen er for smerte eller spasisitet assosiert med multippel sklerose.